Wuhan Hvsen (China) Today
| 300871 Stock | 12.12 0.29 2.45% |
Performance14 of 100
| Odds Of DistressLess than 22
|
Wuhan Hvsen is trading at 12.12 as of the 29th of November 2024, a 2.45 percent increase since the beginning of the trading day. The stock's open price was 11.83. Wuhan Hvsen has about a 22 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat good performance during the last 90 days. Equity ratings for Wuhan Hvsen Biotechnology are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of August 2024 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Wuhan Hvsen is entity of China. It is traded as Stock on SHE exchange. The company has 165.77 M outstanding shares. More on Wuhan Hvsen Biotechnology
Moving together with Wuhan Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Wuhan Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Wuhan Hvsen's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Wuhan Hvsen or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman GM | Weiyuan Zhang | ||||
| Thematic Idea | Biotech (View all Themes) | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
Wuhan Hvsen's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Wuhan Hvsen's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsWuhan Hvsen can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Wuhan Hvsen's financial leverage. It provides some insight into what part of Wuhan Hvsen's total assets is financed by creditors.
| |||||
Wuhan Hvsen Biotechnology (300871) is traded on Shenzhen Stock Exchange in China and employs 1,068 people. Wuhan Hvsen is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.07 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Wuhan Hvsen's market, we take the total number of its shares issued and multiply it by Wuhan Hvsen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Wuhan Hvsen Biotechnology operates under Biotechnology sector and is part of Health Care industry. The entity has 165.77 M outstanding shares.
Wuhan Hvsen generates positive cash flow from operations, but has no cash available
Check Wuhan Hvsen Probability Of Bankruptcy
Ownership AllocationWuhan Hvsen Biotechnology retains a total of 165.77 Million outstanding shares. Wuhan Hvsen Biotechnology maintains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 60.51 (%) of Wuhan Hvsen Biotechnology outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Wuhan Ownership Details
Wuhan Hvsen Biotechnology Risk Profiles
Although Wuhan Hvsen's alpha and beta are two of the key measurements used to evaluate Wuhan Hvsen's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.52 | |||
| Semi Deviation | 2.96 | |||
| Standard Deviation | 3.6 | |||
| Variance | 12.93 |
Wuhan Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Wuhan Hvsen without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Backtesting Now
Portfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfolios |
| All Next | Launch Module |
Wuhan Hvsen Corporate Directors
| Kaijie Yang | Deputy Director | Profile | |
| Jian Zhou | Director HR | Profile | |
| Zexiang Liu | Director GM | Profile | |
| Hongxia Li | Director Supervisor | Profile |
Other Information on Investing in Wuhan Stock
Wuhan Hvsen financial ratios help investors to determine whether Wuhan Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Wuhan with respect to the benefits of owning Wuhan Hvsen security.